Product Description
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Bangladesh | Belgium | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Greece | Hong Kong | Hungary | India | Indonesia | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Menarini
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Irritable Bowel Syndrome|Spasm|Abdominal Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
The DOMINO trial: Diet Or Medication in Irritable bowel syNdrOme | P4 |
Completed |
Spasm|Irritable Bowel Syndrome|Abdominal Pain |
2019-11-14 |
|
Randomized Prospective Trial | P4 |
Completed |
Spasm |
2013-05-01 |
|
DW-TRP001 | P4 |
Unknown status |
Irritable Bowel Syndrome |
2013-02-01 |
|
2005-001655-38 | P4 |
Completed |
Irritable Bowel Syndrome |
2007-03-06 |